CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
1.480
+0.060 (4.23%)
Jul 25, 2025, 4:00 PM - Market closed

Company Description

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.

It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma.

The company’s hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-FcγRIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.

It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C.

to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.

CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals logo
CountryChina
Founded1991
IPO DateJun 11, 1996
IndustryBiotechnology
SectorHealthcare
Employees233
CEODavid Cory

Contact Details

Address:
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road
Beijing, 100025
China
Phone86 10 6508 6063
Websitecasipharmaceuticals.com

Stock Details

Ticker SymbolCASI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000895051
CUSIP Number14757U208
ISIN NumberUS14757U2087
Employer ID58-1959440
SIC Code2836

Key Executives

NamePosition
Dr. Wei-Wu He Ph.D.Chairman and Chief Executive Officer
Dr. Alexander A. Zukiwski M.D.Executive Vice President and Global Chief Medical Officer
Dr. Wei Zhang Ph.D.Senior Vice President
Kun QianVice President and Global Controller
Chunhua WangChief Operating Officer
Wei GaoSenior Vice President and General Counsel
Dr. James E. Goldschmidt Ph.D.Chief Business Development Officer
Hai HuangGlobal Chief Commercial Officer and GM of CASI China

Latest SEC Filings

DateTypeTitle
Feb 20, 2024SC 13D/A[Amend] General statement of acquisition of beneficial ownership
Mar 24, 2023EFFECTNotice of Effectiveness
Mar 22, 202315-12GSecurities registration termination
Mar 21, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Mar 21, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Mar 21, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Mar 21, 2023S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Mar 21, 2023POS AMPost-Effective amendments for registration statement
Mar 21, 20238-KCurrent Report
Feb 21, 2023SC 13D/A[Amend] General statement of acquisition of beneficial ownership